Journal
MOVEMENT DISORDERS
Volume 31, Issue 3, Pages 417-421Publisher
WILEY
DOI: 10.1002/mds.26483
Keywords
Parkinson's disease; antioxidant; uric acid; urate; inosine
Categories
Funding
- Michael J. Fox Foundation for Parkinson's Research
- Department of Defense [W81XWH-11-1-0150]
- Granite State Development
- Harvard NeuroDiscovery Center
Ask authors/readers for more resources
IntroductionHigher serum urate predicts slower progression in PD. The aim of this work was to assess whether oral inosine alters antioxidant capacity of plasma or CSF or urinary markers of oxidative injury in early PD. MethodsWe assayed plasma and CSF antioxidant capacity by ferric-reducing antioxidant power and measured DNA oxidation adduct 8-hydroxydeoxyguanosine from urine in Safety of URate Elevation in PD, a randomized, placebo-controlled trial of oral inosine assessing safety of elevating serum urate from <6 mg/dL to 6.1-7.0 or 7.1-8.0 mg/dL in patients with early PD. ResultsAt 6 months, antioxidant capacity was 29% higher among mild and 43% higher among moderate group participants compared to placebo and correlated with change in serum urate (r = 0.86) and inversely with rate of clinical decline (r=-0.26). CSF antioxidant capacity and urine 8-hydroxydeoxyguanosine did not differ. ConclusionsThe findings demonstrate a dose-dependent, persistent elevation of plasma antioxidant capacity from oral inosine of potential therapeutic relevance. (c) 2016 International Parkinson and Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available